Title

Prophylactic Antimicrobial Catheter Lock
Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    303
This is a randomized, double blinded, prospective, multicenter, clinical trial of the use of Heparin versus Gentamicin as a pos-dialysis catheter lock solution.
The study is a randomized, double blinded, prospective, multicenter, clinical trial. All patients requiring vascular access with a tunneled central venous catheter for hemodialysis are eligible for enrollment. Patients will be randomized to receive either Heparin 1,000 U/ml in a volume sufficient to fill the catheter length in both ports or to receive 4% Sodium Citrate with Gentamicin 320 mcg/mL in a volume sufficient to fill the catheter length in both ports.We hypothesize that the device related infection rate in the Citrate/Gentamicin group will be less than the heparin arm.
Study Started
Sep 30
2003
Primary Completion
Jan 31
2010
Study Completion
Jan 31
2010
Results Posted
Sep 22
2021
Last Update
Sep 22
2021

Drug Heparin 1000U/mL

A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis

Drug 4% Sodium Citrate with Gentamicin 320 mcg/mL

A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis

1 Active Comparator

Catheter lock with heparin 1,000 units/mL

2 Active Comparator

Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%

Criteria

Inclusion Criteria:

Requires placement of a central venous catheter or currently has a central venous catheter for hemodialysis access.
Must be at least 18 years old
Compliant with a dialysis treatment schedule
Plans to continue hemodialysis treatment and follow-up at the investigational site
Must be able to care for the exit site independently or have someone who is able to care for the site for them
Must be able to sign the informed consent document

Exclusion Criteria:

The subject who has had an infection associated with one or more positive blood cultures is not eligible until 14 days after blood cultures have become negative and clinical resolution of the episode has occurred
Active exit site or tunnel infection
Systemic or localized infection that is unresponsive to antibiotic therapy and/or is life threatening
Known to have antibodies to heparin
Allergy to pork heparin
Allergy to gentamicin
Subject is pregnant
Known intravenous drug abuse

Summary

1: Heparin Lock

2: Gentamicin Lock

All Events

Event Type Organ System Event Term 1: Heparin Lock 2: Gentamicin Lock

Rate of Device-related Bacteremia

Positive blood cultures in a patient whose vascular access is a central venous catheter without another obvious source of infection

1: Heparin Lock

30.0
Number of infections

2: Gentamicin Lock

11.0
Number of infections

Rate of Catheter Clotting Measured as Requirement for tPA Usage to Maintain Blood Flow

The rate of thrombolytic agent use required to maintain blood flow adequate for dialysis was used as an objective measure of clinically significant catheter clotting.

1: Heparin Lock

3.42
tPA use/1,000 catheter-days

2: Gentamicin Lock

2.36
tPA use/1,000 catheter-days

Total

303
Participants

Age, Continuous

63.1
years (Mean)
Standard Deviation: 14.8

Diabetes

171
Participants

Dialysis vintage in Months

43.32
months (Median)
Full Range: 0.0 to 198.5

Incident Catheters

20
Participants

Catheter site

Region of Enrollment

Sex: Female, Male

Overall Study

1: Heparin Lock

2: Gentamicin Lock